Overview

Abstract Objective: Adebrelimab is a PD-L1 inhibitor. The aim of this trial is to evaluate the safety and efficacy of adebrelimab combined with SOX regimen for preoperative neoadjuvant therapy in locally advanced gastric adenocarcinoma.

Methods and analysis: This study is a prospective single-center, two-arm, double-blind and randomized controlled clinical trial designed to include 110 patients with locally advanced gastric adenocarcinoma who will be randomly assigned into two groups: experimental group (adebrelimab combined with SOX regimen) (n=55) and control group (SOX regimen) (n=55). The main efficacy indicators are pathological complete response rate (pCR). The secondary efficacy indicators are R0 resection rate, safety indicators (including surgical and drug treatment safety indicators). disease-free survival (DFS) and overall survival (OS).

Ethics: Ethics approval has been obtained from the Ethics Committee at the First Affiliated Hospital (Xijing Hospital) of Air force Military Medical University (KY20232357-F-1).

Eligibility

The inclusion criteria is as follows:

        Patients are able to and willing to provide written informed consent to participate in the
        study.
        Patients are aged 18-75 years old with an Eastern Cooperative Oncology Group (ECOG) score:
        0-1 points and expected survival time ≥ 12 weeks.
        Patients are diagnosed with gastric adenocarcinoma by pathological examination and the
        clinical stage should be clinical stage III (T3-4a/N+M0, T3-4a/N-M0), the tumor of the
        patients with adenocarcinoma of the gastroesophageal junction should be not involve the
        dentate line.
        Functions of the major organs and bone marrow meet the following criteria within 7 days
        before treatment: hemoglobin ≥ 90g/L, absolute neutrophil count ≥ 1.5 × 109/L, platelet
        (PLT) ≥ 80× 109/L, without blood transfusion within 14 days, total bilirubin (TBIL) ≤ 1.5
        times the upper limit of normal (ULN), Alanine aminotransferase (ALT) and aspartate
        aminotransferase (AST) ≤ 2.5x ULN, serum creatinine ≤ 1.5x ULN or creatinine clearance ≥
        60mL/min.
        Doppler ultrasound: Left ventricular ejection fraction (LVEF) ≥ lower limit of normal value
        (50%).
        Have not received anti-tumor treatment (such as surgery, radiotherapy, chemotherapy,
        targeted therapy, immunotherapy).
        The exclusion criteria is as follows:
        Other malignant tumors that have occurred or are currently present within 5 years,
        excluding cured cervical cancer in situ, non-melanoma skin cancer, and superficial bladder
        tumors.
        Patients who require systemic treatment with corticosteroids (>10mg prednisone equivalent
        dose per day) or other immunosuppressive drugs within 14 days before the start of
        treatment.
        Patients with significant malnutrition. Patients receiving live/attenuated vaccines during
        treatment. Patients with any severe and/or uncontrollable diseases, including hypertension
        who cannot be well controlled with antihypertensive medication (systolic blood pressure ≥
        150mm Hg, diastolic blood pressure ≥ 100mm Hg); grade I or above myocardial ischemia or
        infarction, arrhythmia (including QTc ≥ 480ms) and ≥ grade 2 congestive heart failure (New
        York Heart Association (NYHA) classification); severe or uncontrolled active infections (≥
        CTCAE2 level infection); renal failure requires hemodialysis or peritoneal dialysis;
        patients with a history of immune deficiency, including those who are HIV positive or
        suffer from other acquired or congenital immune deficiency diseases; poor blood glucose
        control in diabetes patients (fasting blood glucose (FBG)>10mmol/L); patients with
        epileptic seizures who require treatment; patients with previous and current history of
        interstitial lung disease, pulmonary fibrosis, interstitial pneumonia, pneumoconiosis,
        radiation pneumonia, drug-related pneumonia, severe impairment of lung function, etc., may
        interfere with the detection and management of suspected drug-related pulmonary toxicity;
        patients with gastrointestinal bleeding, perforation, or obstruction.
        Patients with any bleeding event ≥ CTCAE3 level within the first 4 weeks of enrollment, as
        well as patients with unhealed wounds, ulcers, or fractures.
        Patients who have experienced arterial/venous thrombosis events within 3 months, such as
        cerebrovascular accidents (including temporary ischemic attacks), deep vein thrombosis and
        pulmonary embolism.
        Patients who are preparing to undergo or have previously received allogeneic organ or bone
        marrow transplantation.
        According to the judgment of the researchers, patients with other accompanying diseases
        that seriously endanger patient safety or affect the completion of the study.